- 01FY27 revenue forecast: $19m-$20m; EBITDA: $1m-$1.5m.
- 02Contracts and reset expected to restore positive earnings.
- 03$7m upgrades target higher-value CDMO work.
IDT Australia (ASX: IDT) is expecting a return to positive operating earnings in the 2027 financial year as higher-value pharmaceutical manufacturing contracts begin contributing to its revenue base.
The Melbourne-based manufacturer forecasts revenue of $19 million to $20m, representing growth of 13% to 19% from the $16.8m recorded in FY26.
EBITDA are forecast at $1m to $1.5m, compared with a $0.92m loss in the previous year, with the improvement expected to be supported by committed customer programs starting in the second half of FY27 and a strategic reset intended to reduce uneven revenue generation.
The company’s longer-term objective is to lift annual revenue to $50m within three years through expanded markets, stronger customer relationships, and increased demand for specialist services.
Higher-Value Contracts
IDT began the reset early in FY26 to build a more resilient mix of customers and projects across its three operating verticals.
The business has been prioritising larger, better-resourced pharmaceutical and biotechnology customers capable of supporting longer-term development and manufacturing arrangements.
It is building a broader backlog of work to limit dependence on individual contracts and better use manufacturing capacity when customer programs are delayed.
"It is pleasing to see the early benefits from our strategic reset undertaken over a year ago, which is transforming IDT into a stronger, more focused organisation with improving earnings quality, a growing pipeline of potential work and expanding capabilities,” executive chair Mark Simari said.
“Importantly, the growth uplift is being driven by a higher-quality customer base, larger programs, and more diversified revenue streams, providing a stronger foundation for sustained profitability.”
Longer-Term Ambitions
Around $7m is being invested in manufacturing upgrades covering specialist oral dosage forms and advanced sterile production at its Boronia facilities in Victoria.
The program is intended to expand manufacturing capability and help IDT compete for larger, higher-value contracts in specialist contract development and manufacturing organisation (CDMO) services.
IDT has already linked the investment to a further five-year contract with an existing radiopharmaceutical customer, providing an additional source of work over an extended period.
The manufacturer is also developing its relationship with Sanofi, with potential opportunities to move beyond research and development activities into broader manufacturing assignments.
Marginal FY27 Improvement
The FY27 outlook represents a forecast EBITDA improvement of $1.9m to $2.4m rather than a completed turnaround, with much of the expected uplift still dependent on contract execution.
IDT is seeking to smooth the irregular timing of manufacturing revenue by maintaining a deeper pipeline across all three verticals instead of relying on a handful of large projects.
The new capabilities are intended to support repeat manufacturing work, with additional customer programs needed to translate the investment into recurring revenue.
Its three-year revenue ambition remains a target rather than financial guidance for a specific later year, and the planned expansion will depend on customer demand and delivery of the reset.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.
